logo

CRVS

Corvus·NASDAQ
--
--(--)
--
--(--)

CRVS fundamentals

Corvus (CRVS) released its earnings on Mar 12, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.15 (YoY +16.67%), missed estimates.
Revenue / YoY
0
--
EPS / YoY
-0.15
+16.67%
Report date
Mar 12, 2026
CRVS Earnings Call Summary for Q4,2025
  • $246M Cash Runway: Supports trials through Q2 2028.
  • AD Breakthrough: 75% EASI 75 in 8 weeks with no rebound,优于Dupixent and Rinvoq.
  • Broad Pipeline: Expanding into HS, asthma, and ALPS with unique ITK mechanism.
  • Safety: No major signals in >150 patients, including immunocompromised.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

Corvus (CRVS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Corvus (CRVS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

Corvus (CRVS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

Corvus (CRVS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does Corvus (CRVS) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track Corvus (CRVS) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield